Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

Berghmans, Thierry; Paesmans, Marianne; Lalami, Yassine; Louviaux, I.; Luce, Sylvie; Mascaux, Céline; Meert, Anne-Pascale; Sculier, Jean-Paul

doi:10.1016/s0169-5002(02)00180-0

Cited by 172 publications

(100 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the late 1980's and 1990's, randomized trials evaluated the efficacy of multiple single-agent chemotherapeutics including anthracyclines, topoisomerase inhibitors, taxanes, alkylating agents, and platinum analogues in MPM with low response rates of 0-13%, progression free survival of 2-5 months, and median overall survival ranging 5-8 months (39)(40)(41)(42)(43) (36,44).…”

Section: Cytotoxic Chemotherapy For Mpmmentioning

confidence: 99%

Novel systemic therapy against malignant pleural mesothelioma

Mancuso

Neal

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum analog, an anti-metabolite, and sometimes anti-angiogenic therapy, but there is currently no well-established standard therapy for refractory or relapsed disease. This review focuses on efforts to develop improved systemic therapy for the treatment of malignant pleural mesothelioma (MPM) including cytotoxic systemic therapy, a variety of tyrosine kinase inhibitors and their downstream effector pathways, pharmacologic targeting of the epigenome, novel approaches to target proteins expressed on mesothelioma cells (such as mesothelin), arginine depletion therapy, and the emerging role of immunotherapy. Overall, these studies demonstrate the challenges of improving systemic therapy for MPM and highlight the need to develop therapeutic strategies to control this disease.

show abstract

Section: Cytotoxic Chemotherapy For Mpmmentioning

confidence: 99%

Novel systemic therapy against malignant pleural mesothelioma

Mancuso

Neal

2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…It has been suggested that during latency, mutation and/or selection of tumor cells with enhanced resistance to apoptosis results in malignant mesothelioma with high resistance to treatment (10). Cisplatin is currently the most effective single-agent chemotherapy treatment but achieves only a moderate response rate of 28% (11) and a median survival of 10 months (1). In cisplatin-resistant and chemonaive mesothelioma patients, a response rate of 20% and an overall survival of 32 weeks were achieved by combination chemotherapy with oxaliplatin and the folate analogue raltitrexed (Tomudex), which inhibits the activity of thymidylate synthase (TS; ref.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma

Flynn

Berg

Wong

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Malignant mesothelioma is an aggressive tumor of the serosal surfaces of the lungs, heart, and abdomen. Survival rates are poor and effective treatments are not available. However, recent therapeutic regimens targeting thymidylate synthase (TS) in malignant mesothelioma patients have shown promise. We have reported the use of an antisense oligodeoxynucleotide targeting TS mRNA (antisense TS ODN 83) to inhibit growth of human tumor cells. To test the potential for antisense targeting of TS mRNA in treatment of malignant mesothelioma, we assessed and compared the effects of antisense TS ODN 83 on three human malignant mesothelioma cell lines (211H, H2052, and H28) and human nonmalignant mesothelioma cells (HT29 colorectal adenocarcinoma, HeLa cervical carcinoma, and MCF7 breast tumor cell lines). We report that ODN 83 applied as a single agent effectively reduced TS mRNA and protein in malignant mesothelioma cell lines. Furthermore, it inhibited malignant mesothelioma growth significantly more effectively than it inhibited growth of nonmalignant mesothelioma human tumor cell lines: a difference in susceptibility was not observed in response to treatment with TS proteintargeting drugs. In malignant mesothelioma cells, antisense TS both induced apoptotic cell death and reduced proliferation. In nonmalignant mesothelioma cells, only reduced proliferation was observed. Thus, antisense TSmediated induction of apoptosis may be the basis for the high malignant mesothelioma sensitivity to antisense targeting of TS. Further preclinical and clinical study of TS antisense oligodeoxynucleotides, alone and in combination with TS-targeting chemotherapy drugs, in mesothelioma is warranted.

show abstract

“…A large number of single agents have been tested for activity in MPM (Berghmans et al, 2002;Ellis et al, 2006;Sørensen, 2008). The third generation vinca alkaloid vinorelbine has attracted interest in a phase II trial using vinorelbine 30 mg m À2 i.v.…”

mentioning

confidence: 99%

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

2008

View full text Add to dashboard Cite

The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically verified malignant pleural mesothelioma (MPM), normal organ function, and performance status 0 -2. Treatment was vinorelbine 25 mg m À2 i.v. weekly and cisplatin 100 mg m À2 i.v. every 4 weeks with hydration and standard prophylactic antiemetic treatment. Patients gave written informed consent. Characteristics of 54 consecutive patients were: males 85%, epithelial subtype 74%, IMIG stages III and IV 35 and 46%, performance status 0, 1, and 2, 26, 69, and 6%, and median age 63 years (31 -78 years). CTC grade 3 or 4 toxicity occurred with respect to leukocytopenia (48% of patients, grade 4 in 13%), nausea (13%), neurotoxicity (11%), nephrotoxicity (4%), and other toxicities (9%). There were no toxic deaths. The median number of cycles was four. The fraction of patients alive at 1-, 2-, and 3-years were 61, 31, and 4%, respectively, and median survival and median time to progression were 16.8 months (0.5 to 46.4 þ months) and 7.2 months (1.6 to 40.6 þ months). There were two CRs and 14 PRs (response rate 29.6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.

show abstract

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

Cited by 172 publications

References 82 publications

Novel systemic therapy against malignant pleural mesothelioma

Novel systemic therapy against malignant pleural mesothelioma

Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

Contact Info

Product

Resources

About